NYU Langone Health
For this study, high risk prostate cancer patients with lower risk ARTERA scores will be treated with 6 months of Androgen Deprivation Therapy (ADT) in conjunction with dose escalated radiotherapy to the prostate and nodes. Specifically, patients enrolled in this study will undergo one of several dose-escalated forms of radiotherapy which would include SBRT with or without a brachytherapy boost.
Inclusion Criteria: * Ability to understand and willingness to sign a written informed consent document * 18 years of age or older male participants * Biopsy proven prostate cancer meeting at least one of the following high-risk criteria: Gleason score 8-10 OR; Baseline PSA \>20 up to and including 40 ng/ml OR; Patients with Gleason score 6-7 remain eligible if the PSA criterion (\>20 ng/mL) is met OR; MRI Radiographic stage T1-T3 disease without evidence of nodal involvement * No imaging evidence of nodal metastases on baseline MRI/ CT of the pelvis and PET-PSMA scans * Low risk or intermedi…
ADT will be delivered with monthly Degarelix, or Leuprolide injections or daily Relugolix pills which are all standard ADT interventions.
Dose-escalated radiotherapy.
Arctuva estimate
Verify or correct the compensation shown for this listing.